Tipirneni Praveen P. 4

What Happened Praveen P. Tipirneni, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), received a grant/award of derivative securities covering 31,675 shares on 2026-06-16. The Form 4 reports an acquisition price of $0.00 and total reported value $0 because this is a grant of a derivative (stock option/award), not a cash purchase or immediate sale.

Key Details

• Transaction date: 2026-06-16; Filing date: 2026-06-18 (Form 4 accession 0001193125-26-276050).
• Transaction type: Award/Grant of derivative securities (code A); 31,675 shares reported; price reported $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The underlying shares vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the next Annual Meeting of Stockholders, subject to continued service (see F1).
• Remarks: Exhibit 24 (Power of Attorney) attached to the filing.
• Timeliness: Filed within two business days of the transaction date (no late filing indicated).

Context This was a grant of derivative securities (an award/option), which does not reflect an immediate cash outlay or sale of shares. Vesting and any exercise terms will determine when (or if) Tipirneni acquires the underlying shares; the filing does not show exercise, sale, or a strike price. Grants to directors are common as compensation and do not alone indicate a buy/sell signal.